{
  "docId": "019de077-5087-71ae-b0e8-0abfd1317859",
  "docSlug": "b6fff97596ca7cba1b2ee8405a1dc7cd",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 38 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 30,
  "pageCount": 38,
  "prevPage": 29,
  "nextPage": 31,
  "slideType": "appendix_data",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 5,
  "notes": "The slide uses a matrix structure to categorize clinical assets by disease stage and biomarker status (IO sensitive, EGFRm, etc.).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-5087-71ae-b0e8-0abfd1317859/30",
  "deckHref": "/decks/019de077-5087-71ae-b0e8-0abfd1317859",
  "deckJsonHref": "/decks/019de077-5087-71ae-b0e8-0abfd1317859.json",
  "deckAnchorHref": "/decks/019de077-5087-71ae-b0e8-0abfd1317859#slide-30",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.68,
        "x": 0.03,
        "y": 0.22
      },
      "kind": "chart",
      "text": "Clinical trial and drug portfolio matrix",
      "attrs": null,
      "subkind": "matrix-nxn",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "31e75928-0fd0-4b79-8550-cef02d38bfce",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.24,
        "x": 0.74,
        "y": 0.22
      },
      "kind": "list",
      "text": "Leading the future of lung cancer treatment: Establishing Tagrisso as backbone TKI, Imfinzi leading IO, Advancing ADCs, Delivering bispecifics, Investing in new tech.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "abd8468b-5845-47aa-a649-c4c9e7bef1df",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.35,
        "x": 0.02,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "30 Collaboration partners: Daiichi Sankyo (Enhertu, Dato-DXd), Compugen (rilvegestomig). Appendix: Glossary.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "180ddd6f-00a5-48ec-8550-44cb762ebf78",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.7,
        "x": 0.03,
        "y": 0.13
      },
      "kind": "title",
      "text": "Ambition for >50% of lung cancer patients to be eligible for AZN medicine by 2030",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b5e02dad-3e58-4b68-89e4-2c681cfb8ade",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "AstraZeneca in Lung Cancer",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cef38772-cddc-4e18-ae07-f5646bc77707",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "matrix-nxn",
      "slug": null,
      "matchId": "b6dd0f07-4ea1-4107-8b47-8d611d1d8c78",
      "evidence": "The slide organizes clinical assets into a grid based on disease stage and patient type.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}